Alkosign (543453)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 12.78% suggests some return on capital employed, if it can be sustained.
• Latest quarter sales of ₹26 Cr provide a revenue base that could support a turnaround if margins recover.
• The stock is trading at its 52-week high, indicating current market optimism about the business.
• Low market cap of ₹90 Cr leaves room for growth if fundamentals improve materially.

Concerns

• P/E of 86.34 is extremely expensive for a company with profit growth of -88.22%.
• Latest quarter net profit of ₹0 Cr means current earnings provide no valuation support.
• Piotroski F-Score of 3/9 signals poor financial health and operating weakness.
• Zero dividend yield and missing promoter holding/book value data limit transparency and shareholder return.

AI Analysis

This business fails my first test: a durable, understandable moat. Alkosign operates in stationary, but the numbers tell a story of distress. Sales have contracted by 5.59%, and profit has collapsed by 88.22%. In the latest quarter, sales were ₹26 Cr, yet net profit was ₹0 Cr. When earnings vanish, valuation becomes unreliable. A P/E of 86.34 on a market cap of ₹90 Cr means investors are paying for perfection while results are far from perfect. At ₹123.45—the top of the 52-week range—I see no margin of safety. The Piotroski F-Score of 3/9 deepens my caution. It signals weak profitability, poor operating efficiency, and deteriorating financial health. ROCE of 12.78% is a lone bright spot, but with sales shrinking and profits near zero, that return may not endure. There is no dividend to reward patience. Promoter holding and book value are not available, so I cannot judge insider commitment or asset backing. This is not a fast grower or a stalwart; it is a turnaround case that must prove itself. I need evidence that sales have stabilised, costs are under control, and positive profit is sustainable. The stock already trades at its 52-week high, so much good news may be priced in. Wait for several quarters of rising revenue and meaningful net profit before treating this as an investment. Until then, it belongs on the watchlist, not in a portfolio.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer